64113-86-6

Basic information

• Product Name: 5-METHYL-2-NITROBENZONITRILE
• Synonyms: Benzonitrile,5-Methyl-2-nitro-
• CAS NO: 64113-86-6
• Molecular Formula: C₈H₆N₂O₂
• Molecular Weight: 162.15
• Product Categories: Aromatic Nitriles
• Mol File: 64113-86-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 338.9 °C at 760 mmHg
• Flash Point: 158.8 °C
• Appearance: /
• Density: 1.26 g/cm³
• Vapor Pressure: 9.52E-05mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-METHYL-2-NITROBENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-2-NITROBENZONITRILE(64113-86-6)
• EPA Substance Registry System: 5-METHYL-2-NITROBENZONITRILE(64113-86-6)

Safety Data

• Hazardous Substances Data: 64113-86-6(Hazardous Substances Data)

Usage

General Description

5-Methyl-2-nitrobenzonitrile is a chemical compound with the molecular formula C8H6N2O2. It is a yellow crystalline solid that is commonly used as an intermediate in the synthesis of various organic compounds. This chemical is known for its nitro and nitrile functional groups, making it a useful building block for pharmaceuticals, dyes, and agrochemicals. It is also used in the production of specialty chemicals and as a reagent in organic synthesis. 5-Methyl-2-nitrobenzonitrile is considered to be a hazardous substance and should be handled with care due to its potential health and environmental risks.

InChI:InChI=1/C8H6N2O2/c1-6-2-3-8(10(11)12)7(4-6)5-9/h2-4H,1H3

Upstream product

• 65152-29-6 (5-methyl-2-nitro-phenyl)-pyruvic acid 
• 620-22-4 3-Methylbenzonitrile 
• 4315-12-2 5-methyl-2-nitrobenzamide 
• 544-92-3 copper(I) cyanide 
• 38939-88-7 2-chloro-4-methyl-1-nitrobenzene 
• 7664-93-9 sulfuric acid 
• 13435-20-6 tetraethylammoniumcyanide 
• 3113-72-2 5-methyl-2-nitrobenzoic acid 
• 1448721-86-5 C₈H₈N₂O₃ 
• 38818-49-4 5-methyl-2-nitrobenzoyl chloride 

Downstream Products

• 939970-59-9 2-benzylsulfanyl-5-methylbenzonitrile 
• 1427420-60-7 C₂₀H₂₁NO₅S 
• 227016-67-3 5-(bromomethyl)-2-nitrobenzonitrile 
• 64113-84-4 2-fluoro-5-methylbenzonitrile 
• 89-56-5 5-Methylsalicylic acid 
• 63089-50-9 4-methylphthalonitrile 
• 19181-53-4 6-methyl-3H-quinazolin-4-one 
• 2941-78-8 2-Amino-5-methylbenzoic acid 
• 95225-61-9 N,N'-(6-methyl-2,4-quinazolinediyl)bisbenzamide 
• 1955-61-9 6-methyl-2,4-quinazolinediamine 
• 97191-89-4 N,N'-<6-(bromomethyl)-2,4-quinazolinediyl>bisbenzamide 
• 111783-35-8 6-{[Methyl-(3-trifluoromethyl-phenyl)-amino]-methyl}-quinazoline-2,4-diamine 
• 111783-48-3 6-{[(3,4-Dichloro-phenyl)-propyl-amino]-methyl}-quinazoline-2,4-diamine 
• 111783-42-7 6-{[(2,5-Dichloro-phenyl)-methyl-amino]-methyl}-quinazoline-2,4-diamine 

Relevant articles and documents

Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL)

Development of potent small molecule inhibitors of protein-protein interactions with optimized druglike properties represents a challenging task in lead optimization process. Here, we report synthesis and structure-based optimization of new thienopyrimidine class of compounds, which block the protein-protein interaction between menin and MLL fusion proteins that plays an important role in acute leukemias with MLL translocations. We performed simultaneous optimization of both activity and druglike properties through systematic exploration of substituents introduced to the indole ring of lead compound 1 (MI-136) to identify compounds suitable for in vivo studies in mice. This work resulted in the identification of compound 27 (MI-538), which showed significantly increased activity, selectivity, polarity, and pharmacokinetic profile over 1 and demonstrated a pronounced effect in a mouse model of MLL leukemia. This study, which reports detailed structure-activity and structure-property relationships for the menin-MLL inhibitors, demonstrates challenges in optimizing inhibitors of protein-protein interactions for potential therapeutic applications.

Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches

New metabolism blocked antifolates and their salts are provided along with new indications (coronary heart disease, cardiovascular diseases, stroke and termination of tubal or ectopic pregnancy) and methods (sublingual dosage forms, filmstrips or patches) for their use and delivery. Sublingual dosage forms or trans-dermal patches of metabolically blocked entities of this invention offer superior alternatives to traditional oral dosage forms to achieve greater and predictable therapeutic efficacy, lower toxicity and to overcome drug resistance by virtue of elimination of oxidative deactivation and production of toxic metabolites. Metabolism blocked antifolates bearing a fluorinated benzene ring, a thiophene ring, a pyrrole ring, a furan ring or a 8-deazapteridine ring that are provided in this invention are not previously described. The use of metabolism blocked antifolates to terminate medically complicated pregnancies that are taught herein are new inventions targeted to eliminate drug related toxicity to the host and to enhance therapeutic efficacy.

Process for synthesizing antifolates

This invention relates to a process for synthesizing certain folic acid analogues, which are useful in treating cancer, inflammatory diseases, autoimmune diseases, and are commonly referred to as antifolates. The process employs improved steps for annulation, derivatization and addition reactions to produce the described antifolates from commonly available starting materials.